Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

0QQ6

Roche (0QQ6)

Roche Holding Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QQ6
DateTimeSourceHeadlineSymbolCompany
12/19/202412:00AMUK RegulatoryRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s diseaseLSE:0QQ6Roche Holding Ag
12/18/202412:00AMUK RegulatoryRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solutionLSE:0QQ6Roche Holding Ag
12/13/202412:10AMUK RegulatoryRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindnessLSE:0QQ6Roche Holding Ag
12/13/202412:00AMUK RegulatoryRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilitiesLSE:0QQ6Roche Holding Ag
12/10/202412:00AMUK RegulatoryNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphomaLSE:0QQ6Roche Holding Ag
12/09/20243:30PMUK RegulatoryRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cashLSE:0QQ6Roche Holding Ag
12/08/202411:30AMUK RegulatoryFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphomaLSE:0QQ6Roche Holding Ag
12/05/202412:00AMUK RegulatoryFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphomaLSE:0QQ6Roche Holding Ag
11/26/202412:10AMUK RegulatoryRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologiesLSE:0QQ6Roche Holding Ag
11/26/202412:00AMUK RegulatoryRoche reports update on Phase III SKYSCRAPER-01 study resultsLSE:0QQ6Roche Holding Ag
11/05/20248:15AMUK RegulatoryRoche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024LSE:0QQ6Roche Holding Ag
10/31/20241:15AMUK RegulatoryRoche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s diseaseLSE:0QQ6Roche Holding Ag
10/31/20241:00AMUK RegulatoryNew England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancerLSE:0QQ6Roche Holding Ag
10/23/20244:58AMIH Market NewsUS Futures Fall Amid Treasury Yield Surge and Earnings; Oil Prices Dip as U.S. Crude Inventories RiseLSE:0QQ6Roche Holding Ag
10/23/202412:00AMUK Regulatory[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine monthsLSE:0QQ6Roche Holding Ag
10/23/202412:00AMUK Regulatory[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%LSE:0QQ6Roche Holding Ag
10/18/20244:00PMUK RegulatoryRoche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind studyLSE:0QQ6Roche Holding Ag
10/14/202412:00AMUK RegulatoryMajority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrateLSE:0QQ6Roche Holding Ag
10/11/202412:00AMUK RegulatoryFDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationLSE:0QQ6Roche Holding Ag
10/10/202412:00AMUK RegulatoryRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOYLSE:0QQ6Roche Holding Ag
09/26/202412:00AMUK RegulatoryPositive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritisLSE:0QQ6Roche Holding Ag
09/24/202412:00AMUK RegulatoryRoche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory virusesLSE:0QQ6Roche Holding Ag
09/23/202412:00AMUK RegulatoryWHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutionsLSE:0QQ6Roche Holding Ag
09/19/202412:00AMUK RegulatoryPositive phase III results show Xofluza significantly reduces the transmission of influenza virusesLSE:0QQ6Roche Holding Ag
09/16/202412:00AMUK RegulatoryFDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosisLSE:0QQ6Roche Holding Ag
09/13/202412:00AMUK RegulatoryFDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapyLSE:0QQ6Roche Holding Ag
09/10/20249:00AMUK RegulatoryRoche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigenLSE:0QQ6Roche Holding Ag
09/10/20249:00AMUK RegulatoryRoche opens Pharma Research and Development Center in Basel to accelerate scientific innovationLSE:0QQ6Roche Holding Ag
09/04/20241:00AMUK RegulatoryRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosisLSE:0QQ6Roche Holding Ag
08/27/202412:00AMUK RegulatoryRoche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNHLSE:0QQ6Roche Holding Ag
 Showing the most relevant articles for your search:LSE:0QQ6

Your Recent History

Delayed Upgrade Clock